Austin D. Thompson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Austin D. Thompson has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Jaroslav Janda
Department of Pharmacology and Toxicology, University of Arizona, Tucson, Arizona
5 shared publications- Rick G. Schnellmann
University of Arizona
5 shared publications - Natalie E. Scholpa
University of Arizona
4 shared publications - Kai W. McAlister
University of Arizona
3 shared publications John Hortareas
University of Arizona
2 shared publicationsBaerbel Rohrer
MitoChem Therapeutics, Inc. Charleston South Carolina USA
1 shared publication
Latest Publications
- 23 March 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (5) , 104321
5-Hydroxytryptamine 2B receptor antagonism restores ATP and reduces tubulointerstitial fibrosis in the renal cortices of aged mice
- 23 March 2026
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 393 (5) , 104321
5-Hydroxytryptamine 2B receptor antagonism restores ATP and reduces tubulointerstitial fibrosis in the renal cortices of aged mice
- Open Access
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 329 (6) , F834-F852
5-Hydroxytryptamine 1F receptor loss reduces renal vasculature and prevents lasmiditan-induced recovery following moderate-severe acute kidney injury in mice
In the present study, we confirmed that lasmiditan-induced renal recovery following moderate-severe bilateral ischemia/reperfusion-induced acute kidney injury (I/R-AKI) in mice is dependent on the HTR1F expression. Furthermore, lasmiditan treatment ameliorated acute tubular injury, mitochondrial dysfunction, tubulointerstitial fibrosis, and renal cortical vascular rarefaction postinjury, likely contributing to this enhanced recovery. Interestingly, we also found that mice lacking the HTR1F display decreased innate renal cortical vasculature, exacerbated rarefaction, and exhibit markedly increased mortality following moderate-severe I/R-AKI.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 329 (6) , F834-F852
Open Access5-Hydroxytryptamine 1F receptor loss reduces renal vasculature and prevents lasmiditan-induced recovery following moderate-severe acute kidney injury in mice
In the present study, we confirmed that lasmiditan-induced renal recovery following moderate-severe bilateral ischemia/reperfusion-induced acute kidney injury (I/R-AKI) in mice is dependent on the HTR1F expression. Furthermore, lasmiditan treatment ameliorated acute tubular injury, mitochondrial dysfunction, tubulointerstitial fibrosis, and renal cortical vascular rarefaction postinjury, likely contributing to this enhanced recovery. Interestingly, we also found that mice lacking the HTR1F display decreased innate renal cortical vasculature, exacerbated rarefaction, and exhibit markedly increased mortality following moderate-severe I/R-AKI.
- 1 April 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (4) , C1318-C1332
Lasmiditan induces mitochondrial biogenesis in primary mouse renal peritubular endothelial cells and augments wound healing and tubular network formation
Lasmiditan, an FDA-approved HTR1F agonist, induces mitochondrial biogenesis (MB) and enhances recovery following acute kidney injury in mice. Renal microvascular endothelial cells (MV-ECs) are highly susceptible to dysfunction/rarefaction postinjury. The effect of MB on MV-EC repair/recovery is unknown. We show that lasmiditan induces MB in primary mouse renal peritubular endothelial cells and improves wound healing, endothelial tubular network formation, and barrier integrity after inflammatory-induced dysfunction, indicative of its potential for the treatment of kidney diseases.
- 1 April 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (4) , C1318-C1332
Lasmiditan induces mitochondrial biogenesis in primary mouse renal peritubular endothelial cells and augments wound healing and tubular network formation
Lasmiditan, an FDA-approved HTR1F agonist, induces mitochondrial biogenesis (MB) and enhances recovery following acute kidney injury in mice. Renal microvascular endothelial cells (MV-ECs) are highly susceptible to dysfunction/rarefaction postinjury. The effect of MB on MV-EC repair/recovery is unknown. We show that lasmiditan induces MB in primary mouse renal peritubular endothelial cells and improves wound healing, endothelial tubular network formation, and barrier integrity after inflammatory-induced dysfunction, indicative of its potential for the treatment of kidney diseases.
- 31 January 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (9) , 1912-1929
MC16 promotes mitochondrial biogenesis and ameliorates acute and diabetic nephropathy
Background and Purpose: Kidney disease (KD) is a leading cause of mortality worldwide, affecting 〉10% of the global population. Two of the most common causes of KD are diabetes and acute kidney injury (AKI), both of which induce mitochondrial dysfunction resulting in renal proximal tubular damage/necrosis. Thus, pharmacological induction of mitochondrial biogenesis (MB) may provide a therapeutic strategy to block the onset/progression of KD. Here, we evaluated the pharmacological and potential therapeutic effects of a novel MB‐inducing oxindole agent, MC16.Experimental Approach: Primary cultures of rabbit renal proximal tubule cells (RPTCs) were used to evaluate the cellular signalling and MB‐inducing effects of MC16. Mice were used to determine the MB‐inducing effects of MC16 in vivo, and the metabolic effects of MC16 on the renal cortical metabolome. Mouse models of AKI and diabetic kidney disease (DKD) were used to demonstrate the therapeutic potential of MC16 to ameliorate acute and diabetic nephropathy.Key Results: MC16 activated the PI3K‐AKT‐eNOS‐FOXO1 axis and induced MB in RPTCs. MC16 induced MB and altered the renal cortical metabolome of mice. MC16 accelerated renal recovery, reduced vascular permeability, and diminished mitochondrial dysfunction following AKI. MC16 decreased diabetes‐induced renal swelling, improved renal and mitochondrial function, and diminished interstitial fibrosis in DKD mouse models.Conclusion and Implications: MC16 is a novel compound that induces MB and ameliorates acute and diabetic nephropathy in mice. This study underscores that targeting MB following the onset of renal/metabolic insults may provide a therapeutic strategy to mitigate the onset and/or progression of KD.
- 31 January 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (9) , 1912-1929
MC16 promotes mitochondrial biogenesis and ameliorates acute and diabetic nephropathy
Background and Purpose: Kidney disease (KD) is a leading cause of mortality worldwide, affecting 〉10% of the global population. Two of the most common causes of KD are diabetes and acute kidney injury (AKI), both of which induce mitochondrial dysfunction resulting in renal proximal tubular damage/necrosis. Thus, pharmacological induction of mitochondrial biogenesis (MB) may provide a therapeutic strategy to block the onset/progression of KD. Here, we evaluated the pharmacological and potential therapeutic effects of a novel MB‐inducing oxindole agent, MC16.Experimental Approach: Primary cultures of rabbit renal proximal tubule cells (RPTCs) were used to evaluate the cellular signalling and MB‐inducing effects of MC16. Mice were used to determine the MB‐inducing effects of MC16 in vivo, and the metabolic effects of MC16 on the renal cortical metabolome. Mouse models of AKI and diabetic kidney disease (DKD) were used to demonstrate the therapeutic potential of MC16 to ameliorate acute and diabetic nephropathy.Key Results: MC16 activated the PI3K‐AKT‐eNOS‐FOXO1 axis and induced MB in RPTCs. MC16 induced MB and altered the renal cortical metabolome of mice. MC16 accelerated renal recovery, reduced vascular permeability, and diminished mitochondrial dysfunction following AKI. MC16 decreased diabetes‐induced renal swelling, improved renal and mitochondrial function, and diminished interstitial fibrosis in DKD mouse models.Conclusion and Implications: MC16 is a novel compound that induces MB and ameliorates acute and diabetic nephropathy in mice. This study underscores that targeting MB following the onset of renal/metabolic insults may provide a therapeutic strategy to mitigate the onset and/or progression of KD.
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 510
The FDA Approved Therapeutic Lasmiditan, Enhances Primary Murine Renal Peritubular Endothelial Cells Wound Healing Capacity.
ID 16703 Poster Board 510 Background: Acute kidney injury (AKI) is defined as an episode of sudden and rapid decline in renal function and is often accompanied by a persistent reduction in mitochondrial function, renal microvasculature dysfunction/rarefication, and tubular injury/necrosis. AKI continues to be an immense public health concern, as there remains no effective FDA-approved treatment options. A central underlying contributor to AKI, and the subsequent development of other progressive kidney and cardiovascular related diseases, is renal microvascular endothelial cell dysfunction/rarefaction. This dysfunction/rarefaction exacerbates renal injury and increases the likelihood of AKI recurrence (∼20%). Furthermore, AKI results in a persistent reduction in mitochondrial function, number, and cellular energetics. Conversely, pharmacological stimulation of mitochondrial biogenesis (MB) has been shown to restore mitochondrial function and promote renal vascular recovery post-AKI. However, minimal AKI research has focused on elucidating the cellular mechanisms that govern mitochondrial biogenesis (MB) and neovascularization responses post-AKI; moreover, how stimulation of MB contributes to renal peritubular endothelial cell repair mechanisms post-AKI remains unknown. Therefore, we conducted in-vitro wound healing assays with primary murine renal peritubular endothelial cells (MRPEC) exposed to lipopolysaccharide (LPS) in the presence/absence of the lasmiditan, a 5-HT1F receptor agonist, and a known inducer of MB within the renal cortex of mice. Methods: MRPECs were isolated utilizing a refined method by Zhao et al. (2014). Briefly, renal enzymatic tissue digestion buffers were altered by replacing collagenase type 4 with collagenase type 1 and trypsin with accutase, respectively. Additionally, gentle MACS-C tubes with automated tissue dissociation were employed to reduce processing times and improve cell viability. Cells were then subjected to CD326+ magnetic microbead negative selection, to remove epithelial cells, followed by two positive selection cycles with CD146+ magnetic microbeads. Purified MRPECs were then seeded at a density of 70,000 cells/well into human plasma fibronectin precoated 35mm Ibidi wound healing chamber dishes and incubated overnight in microvascular specific media (EGM-MV2; Lonza). MRPECs were then treated with either LPS (1ug/mL) or normal saline in the presence/absence of lasmiditan (100nM) prior to the removal of chamber inserts. Wound healing dishes were then imaged at 0-, 6-, and 12- hours post treatment and subsequently analyzed by Ibidi FastTrackAI software. Results: MRPECs treated with lasmiditan displayed an increase in total wound closure percentage, 1.21 and 1.44 fold compared to normal saline and LPS treated control cells, respectively. Additionally, MRPECs treated with both LPS and lasmiditan exhibited an increase in total wound closure percentage, 1.33 fold compared to LPS treated control cells. Lastly, LPS treated MRPECs displayed a decrease in total wound closure percentage compared to normal saline controls, 1.18 fold. Conclusion: In conclusion, we demonstrated that lasmiditan treatment enhanced MRPEC wound healing capacity alone and following LPS induced cellular injury, in-vitro. These results suggest that lasmiditan may promote vascular recovery following kidney injury. T32 5T32ES007091-39 (National Institutes of Health; NIEHS) to ADT. BX000851 (Department of Veterans Affairs) to RGS.
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 510
Open AccessThe FDA Approved Therapeutic Lasmiditan, Enhances Primary Murine Renal Peritubular Endothelial Cells Wound Healing Capacity.
ID 16703 Poster Board 510 Background: Acute kidney injury (AKI) is defined as an episode of sudden and rapid decline in renal function and is often accompanied by a persistent reduction in mitochondrial function, renal microvasculature dysfunction/rarefication, and tubular injury/necrosis. AKI continues to be an immense public health concern, as there remains no effective FDA-approved treatment options. A central underlying contributor to AKI, and the subsequent development of other progressive kidney and cardiovascular related diseases, is renal microvascular endothelial cell dysfunction/rarefaction. This dysfunction/rarefaction exacerbates renal injury and increases the likelihood of AKI recurrence (∼20%). Furthermore, AKI results in a persistent reduction in mitochondrial function, number, and cellular energetics. Conversely, pharmacological stimulation of mitochondrial biogenesis (MB) has been shown to restore mitochondrial function and promote renal vascular recovery post-AKI. However, minimal AKI research has focused on elucidating the cellular mechanisms that govern mitochondrial biogenesis (MB) and neovascularization responses post-AKI; moreover, how stimulation of MB contributes to renal peritubular endothelial cell repair mechanisms post-AKI remains unknown. Therefore, we conducted in-vitro wound healing assays with primary murine renal peritubular endothelial cells (MRPEC) exposed to lipopolysaccharide (LPS) in the presence/absence of the lasmiditan, a 5-HT1F receptor agonist, and a known inducer of MB within the renal cortex of mice. Methods: MRPECs were isolated utilizing a refined method by Zhao et al. (2014). Briefly, renal enzymatic tissue digestion buffers were altered by replacing collagenase type 4 with collagenase type 1 and trypsin with accutase, respectively. Additionally, gentle MACS-C tubes with automated tissue dissociation were employed to reduce processing times and improve cell viability. Cells were then subjected to CD326+ magnetic microbead negative selection, to remove epithelial cells, followed by two positive selection cycles with CD146+ magnetic microbeads. Purified MRPECs were then seeded at a density of 70,000 cells/well into human plasma fibronectin precoated 35mm Ibidi wound healing chamber dishes and incubated overnight in microvascular specific media (EGM-MV2; Lonza). MRPECs were then treated with either LPS (1ug/mL) or normal saline in the presence/absence of lasmiditan (100nM) prior to the removal of chamber inserts. Wound healing dishes were then imaged at 0-, 6-, and 12- hours post treatment and subsequently analyzed by Ibidi FastTrackAI software. Results: MRPECs treated with lasmiditan displayed an increase in total wound closure percentage, 1.21 and 1.44 fold compared to normal saline and LPS treated control cells, respectively. Additionally, MRPECs treated with both LPS and lasmiditan exhibited an increase in total wound closure percentage, 1.33 fold compared to LPS treated control cells. Lastly, LPS treated MRPECs displayed a decrease in total wound closure percentage compared to normal saline controls, 1.18 fold. Conclusion: In conclusion, we demonstrated that lasmiditan treatment enhanced MRPEC wound healing capacity alone and following LPS induced cellular injury, in-vitro. These results suggest that lasmiditan may promote vascular recovery following kidney injury. T32 5T32ES007091-39 (National Institutes of Health; NIEHS) to ADT. BX000851 (Department of Veterans Affairs) to RGS.
- 5 July 2022
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 189 (1) , 62-72
Increased Renal Expression of Complement Components in Patients With Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination
Inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH), alcohol-associated liver disease (ALD), hepatitis C virus (HCV), and ALD/HCV, account for nearly 2 million deaths annually. Despite increasing evidence that liver dysfunction impacts renal physiology, there is limited supportive clinical information, due to limited diagnosis of liver disease, complexity in liver disease etiology, and inadequacy of renal function tests. Human kidney biopsies with liver and renal pathology were obtained from patients with nonalcoholic fatty liver disease (NAFLD), NASH, ALD, HCV, and ALD/HCV (n = 5–7). Each liver disease showed renal pathology with at least 50% interstitial nephritis, 50% interstitial fibrosis, and renal dysfunction by estimated glomerular filtration rate (NAFLD 36.7 ± 21.4; NASH 32.7 ± 15.0; ALD 16.0 ± 11.0; HCV 27.6 ± 11.5; ALD/HCV 21.0 ± 11.2 ml/min/1.73 m2). Transcriptomic analysis identified 55 genes with expression changes in a conserved direction in response to liver disease. Considering association with immune regulation, protein levels of alpha-2-macroglobulin, clusterin, complement C1q C chain (C1QC), CD163, and joining chain of multimeric IgA and IgM (JCHAIN) were further quantified by LC-MS/MS. C1QC demonstrated an increase in NASH, ALD, HCV, and ALD/HCV (42.9 ± 16.6; 38.8 ± 18.4; 39.0 ± 13.5; 40.1 ± 20.1 pmol/mg protein) relative to control (19.2 ± 10.4 pmol/mg protein; p ≤ 0.08). Renal expression changes identified in inflammatory liver diseases with interstitial pathology suggest the pathogenesis of liver associated renal dysfunction. This unique cohort overcomes diagnostic discrepancies and sample availability to provide insight for mechanistic investigations on the impact of liver dysfunction on renal physiology.
- 5 July 2022
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 189 (1) , 62-72
Increased Renal Expression of Complement Components in Patients With Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination
Inflammatory liver diseases, including nonalcoholic steatohepatitis (NASH), alcohol-associated liver disease (ALD), hepatitis C virus (HCV), and ALD/HCV, account for nearly 2 million deaths annually. Despite increasing evidence that liver dysfunction impacts renal physiology, there is limited supportive clinical information, due to limited diagnosis of liver disease, complexity in liver disease etiology, and inadequacy of renal function tests. Human kidney biopsies with liver and renal pathology were obtained from patients with nonalcoholic fatty liver disease (NAFLD), NASH, ALD, HCV, and ALD/HCV (n = 5–7). Each liver disease showed renal pathology with at least 50% interstitial nephritis, 50% interstitial fibrosis, and renal dysfunction by estimated glomerular filtration rate (NAFLD 36.7 ± 21.4; NASH 32.7 ± 15.0; ALD 16.0 ± 11.0; HCV 27.6 ± 11.5; ALD/HCV 21.0 ± 11.2 ml/min/1.73 m2). Transcriptomic analysis identified 55 genes with expression changes in a conserved direction in response to liver disease. Considering association with immune regulation, protein levels of alpha-2-macroglobulin, clusterin, complement C1q C chain (C1QC), CD163, and joining chain of multimeric IgA and IgM (JCHAIN) were further quantified by LC-MS/MS. C1QC demonstrated an increase in NASH, ALD, HCV, and ALD/HCV (42.9 ± 16.6; 38.8 ± 18.4; 39.0 ± 13.5; 40.1 ± 20.1 pmol/mg protein) relative to control (19.2 ± 10.4 pmol/mg protein; p ≤ 0.08). Renal expression changes identified in inflammatory liver diseases with interstitial pathology suggest the pathogenesis of liver associated renal dysfunction. This unique cohort overcomes diagnostic discrepancies and sample availability to provide insight for mechanistic investigations on the impact of liver dysfunction on renal physiology.